Search
NewAmsterdam Pharma Company NV
NAMSAdd to Watchlist
22.680USD
-0.640-2.74%
Close 09-23 16:00（ET）
2.65BMarket Cap
LossP/E TTM
NewAmsterdam Pharma Company NV (NAMS) Stock Price Target & Forecast
Analyst Rating
Based on 17 analysts giving stock ratings to NewAmsterdam Pharma Company NV in the past month.
Buy
7 Strong Buy
9 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
51.800USD+122.13%
NAMS Analyst Recommendation Trends
In the current month, NAMS has received 9 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. NAMS average Analyst price target in the last month is 51.800.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
7
7
7
7
7
7
7
7
9
9
8
8
8
8
7
7
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
17
16
16
16
16
15
15
NAMS Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, NAMS EPS is projected to reach -0.507 in FY2026Q3, following reported EPS of -0.520 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.39
-0.49
-0.49
-0.51
-0.46
Actual
-0.62
-0.40
-0.52
--
--
Surprise
-62.16%
+19.13%
-6.50%
--
--
FAQs
What is NewAmsterdam Pharma Company NV's expected revenue for the next quarter?
NewAmsterdam Pharma Company NV's expected revenue is 7.34M.
What is NewAmsterdam Pharma Company NV's price target?
Analysts forecast that NewAmsterdam Pharma Company NV's price target is USD 51.80, with the highest forecast at USD 60.00 and the lowest forecast at USD 38.00.
How have NewAmsterdam Pharma Company NVNAMS's recent earnings per share performed?
The market expectation was USD -0.52, while NewAmsterdam Pharma Company NVNAMS's earnings per share (EPS) for the previous quarter was USD -0.40. EPS for the next quarter is expected at USD -0.51.
What is the analyst rating for NewAmsterdam Pharma Company NV?
Based on the ratings of NewAmsterdam Pharma Company NV's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.